BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35598596)

  • 1. Waning of SARS-CoV-2 Vaccine-Induced Immune Response over 6 Months in Peritoneal Dialysis Patients and the Role of a Booster Dose in Maintaining Seropositivity.
    Murt A; Dinc HO; Altiparmak MR; Yalin SF; Yadigar S; Parmaksiz E; Kocazeybek B; Pekpak M; Ataman MR
    Nephron; 2022; 146(6):559-563. PubMed ID: 35598596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody responses to inactivated SARS-CoV-2 vaccine in peritoneal dialysis patients.
    Murt A; Altiparmak MR; Ozbey D; Yalin SF; Sert Yadigar S; Karaali R; Kocazeybek B; Saltoglu N; Pekpak M; Ataman MR
    Semin Dial; 2022 May; 35(3):264-268. PubMed ID: 34989454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody responses to the SARS-CoV-2 vaccines in hemodialysis patients: Is inactivated vaccine effective?
    Murt A; Altiparmak MR; Yadigar S; Yalin SF; Ozbey D; Yildiz Z; Kocazeybek B; Pekpak M; Ataman MR
    Ther Apher Dial; 2022 Aug; 26(4):769-774. PubMed ID: 34741418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Humoral Immune Response in Inactivated SARS-CoV-2 Vaccine: When Should a Booster Dose be Administered?].
    Kara E; Tanır F; Demirhindi H; Mete B; Kibar F; Çetiner S; Candevir A; İnaltekin A
    Mikrobiyol Bul; 2022 Jul; 56(3):566-573. PubMed ID: 35960246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis.
    Bensouna I; Caudwell V; Kubab S; Acquaviva S; Pardon A; Vittoz N; Bozman DF; Hanafi L; Faucon AL; Housset P
    Am J Kidney Dis; 2022 Feb; 79(2):185-192.e1. PubMed ID: 34508833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular and humoral immune responses to COVID-19 booster vaccination in Japanese dialysis patients.
    Yoshifuji A; Toda M; Oyama E; Nakayama T; Mise-Omata S; Kikuchi K; Yoshizawa M; Kato N; Wakai H; Koibuchi K; Morimoto K; Uwamino Y; Namkoong H; Shibata A; Wakabayashi K; Fujino M; Komatsu M; Mochizuki N; Kondo N; Yoshimura A; Hasegawa N; Ryuzaki M
    Clin Exp Nephrol; 2024 Jul; 28(7):674-682. PubMed ID: 38457030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dialysis modality, humoral response to vaccine, and SARS-CoV-2 infection risk: Comparative prospective evaluation.
    Bnaya A; Nacasch N; Einbinder Y; Shavit L; Erez D; Shashar M; Grupper A; Benchetrit S; Wand O; Cohen-Hagai K
    Semin Dial; 2023; 36(5):382-389. PubMed ID: 37042666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of homologous and heterologous inactivated and mRNA vaccination programme against SARS-CoV-2 in dialysis patients.
    Yasar E; Yildiz Y; Ozturk E; Gok Oguz E; Coskun Yenigun E; Ozturk R; Helvaci O; Ozger HS; Keles M; Karacin C; Ugras Dikmen A; Caglar K; Duranay M; Ayli MD; Dizbay M; Erten Y; Guz G; Derici U
    Nephrology (Carlton); 2024 Jul; 29(7):405-414. PubMed ID: 38485143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Dynamic Humoral Response to SARS-CoV-2 mRNA Vaccines in Patients on Peritoneal Dialysis.
    Quiroga B; Soler MJ; Ortiz A; Gansevoort RT; Leyva A; Rojas J; de Sequera P;
    Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents.
    Schiavoni I; Palmieri A; Olivetta E; Leone P; Di Lonardo A; Mazzoli A; Cafariello C; Malara A; Palamara AT; Incalzi RA; Onder G; Stefanelli P; Fedele G;
    J Am Med Dir Assoc; 2023 Feb; 24(2):140-147.e2. PubMed ID: 36587928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-SARS-CoV-2 IgG antibody titer after BNT162b2 mRNA COVID-19 vaccination in Japanese patients who underwent renal replacement therapy, hemodialysis, peritoneal dialysis, and kidney transplantation.
    Iwabuchi R; Harada M; Yamada A; Aomura D; Yamada Y; Sonoda K; Nakazawa H; Sakai K; Mizukami E; Hashimoto K; Kamijo Y
    Clin Exp Nephrol; 2023 Aug; 27(8):660-671. PubMed ID: 37095343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine.
    Cucunawangsih C; Wijaya RS; Lugito NPH; Suriapranata I
    Int J Infect Dis; 2022 May; 118():116-118. PubMed ID: 35192955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
    Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients.
    Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E
    Front Immunol; 2022; 13():907615. PubMed ID: 35812459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoassay and mass cytometry revealed immunological profiles induced by inactivated BBIBP COVID-19 vaccine.
    Cheng ZJ; Huang H; Liu Q; Zhong R; Liang Z; Xue M; Liu M; Li S; Wang H; Zheng P; Zheng C; Sun B
    J Med Virol; 2022 Nov; 94(11):5206-5216. PubMed ID: 35801663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humeral and cellular immune responses to SARS-CoV-2 vaccination in patients on peritoneal dialysis.
    Yu ZY; Lai CF; Lai TS; Yang SY; Chen SI; Lai MJ; Kang CM; Huang YT; Chen YT; Hsueh PR; Chen YM; Lin SL
    J Formos Med Assoc; 2023 Sep; 122(9):922-931. PubMed ID: 36894486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunity against Delta and Omicron variants elicited by homologous inactivated vaccine booster in kidney transplant recipients.
    Zhang L; Yang J; Lai C; Wan L; Xiong S; Kong W; Liu Z; Yu P; Chen M; Mai W; Khan SA; Deng M; Chen L; Lei Y; Zhou Q; Yu N; Li P; Chen Z; Ji T
    Front Immunol; 2022; 13():1042784. PubMed ID: 36700230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination.
    Gonzalez-Perez M; Montes-Casado M; Conde P; Cervera I; Baranda J; Berges-Buxeda MJ; Perez-Olmeda M; Sanchez-Tarjuelo R; Utrero-Rico A; Lozano-Ojalvo D; Torre D; Schwarz M; Guccione E; Camara C; Llópez-Carratalá MR; Gonzalez-Parra E; Portoles P; Ortiz A; Portoles J; Ochando J
    Front Immunol; 2022; 13():845882. PubMed ID: 35401504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.